With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Abraxane again fails to live up to its price tag, this time in combo with gemcitabine in a single arm phase 2 trial for cholangiocarcinoma showing no real improvement upon (dismal) historical outcomes. | Sahai, JAMA Oncol 2018